Increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease-Reference-Cited by-同舟云学术

Increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease

Published:2019-07-02 Issue:3 Volume:50 Page:289-294
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Korzenik Joshua¹²,Larsen Michael Due³⁴^ORCID,Nielsen Jan³⁴,Kjeldsen Jens⁵⁶,Nørgård Bente Mertz¹²³⁴

Affiliation:

1. Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine; Brigham and Women’s Hospital; Boston Massachusetts

2. Harvard Medical School; Boston Massachusetts

3. Center for Clinical Epidemiology; Odense University Hospital; Odense Denmark

4. Department of Clinical Research, Research Unit of Clinical Epidemiology; University of Southern Denmark; Odense Denmark

5. Department of Medical Gastroenterology S; Odense University Hospital; Odense Denmark

6. Department of Clinical Research, Research Unit of Medical Gastroenterology; University of Southern Denmark; Odense C Denmark

Funder

University of Odense Hospital Free Research Foundation

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15370/fullpdf

Reference32 articles.

1. Infliximab for the treatment of fistulas in patients with Crohn's disease;Present;N Engl J Med,1999

2. Infliximab for induction and maintenance therapy for ulcerative colitis;Rutgeerts;N Engl J Med,2005

3. Infliximab maintenance therapy for fistulizing Crohn's disease;Sands;N Engl J Med,2004

4. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for RA: the ReAct trial;Burmester;Ann Rheum Dis,2007

5. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases;Kirchgesner;Gastroenterology,2018

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review of dermatologic drugs relevant to inflammatory bowel disease;JAAD Reviews;2024-09

2. Ex vivo cell-based assay for assessment of response to TNF inhibitors in patients with rheumatic diseases;Rheumatology;2024-05-25

3. Etanercept-synthesizing adipose-derived stem cell secretome: A promising therapeutic option for inflammatory bowel disease;World Journal of Gastrointestinal Surgery;2024-03-27

4. Some Drugs Have Two Faces: Paradoxical Colitis in a Patient with Psoriatic Arthritis Previously Treated with Etanercept and IL-17 Inhibitors;Digestive Diseases and Sciences;2024-03-19

5. Colitis-induced upregulation of tumor necrosis factor receptor-2 (TNFR2) terminates epithelial regenerative signaling to restore homeostasis;iScience;2023-10